Genoa Pharmaceuticals
San Diego, US · Founded 2011 · Delaware corporation · 3 known investors
Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Its lead asset is inhaled pirfenidone (Aerodone), a nebulized reformulation designed to deliver effective lung levels while reducing the side effects of oral dosing.
BiotechHealthtech
Founders & leadership
Genoa Pharmaceuticals was founded in 2011 by Mark W. Surber, Ph.D..
MW
Mark W. Surber, Ph.D.Founder
RG
Richard G. VincentExecutive
Board
MJ
Michael J. KamdarBoard director
DD
Daniel D. BurgessBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$245.1M disclosed across 4 rounds · 2011–2023
▶$189.2MraisedOct 2023 · 26 investors · BiotechnologyRule 506(b)
▶$189.2MraisedOct 2023 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lyn BaranowskiExecutive Officer, Director
- Tiba AynechiDirector
- Ketan PatelDirector
- Peter MoldtDirector
- Niall O'DonnellDirector
- Cassandra Gianna LucaDirector
- Jonathan LeffDirector
- Jill CarrollDirector
- Offering amount
- $189.2M
- Amount sold
- $189.2M
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35.5MraisedMay 2020 · 8 investors · BiotechnologyRule 506(b)
▶$35.5MraisedMay 2020 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Niall O'DonnellDirector
- Jonathan LeffDirector
- Sofia IoannidouDirector
- Tiba AynechiDirector
- Heather PrestonDirector
- Ketan PatelDirector
- A. Bruce MontgomeryExecutive Officer, Director
- Robert MittendorffDirector
- Offering amount
- $35.7M
- Amount sold
- $35.5M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.2MraisedMay 2017 · 46 investors · PharmaceuticalsRule 506(b)
▶$18.2MraisedMay 2017 · 46 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan Leff, M.D.Director
- Bruce Montgomery, M.D.Director, Executive Officer
- Ketan PatelDirector
- Naveed SiddiqiDirector
- Heather PrestonDirector
- Niall O'DonnellDirector
- Mark W. Surber, Ph.D.Executive Officer
- Tiba AynechiDirector
- Offering amount
- $64.9M
- Amount sold
- $18.2M
- Minimum investment
- $1
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedAug 2015 · 41 investors · PharmaceuticalsRule 506(b)
▶$2.2MraisedAug 2015 · 41 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. KamdarDirector
- Daniel D. BurgessDirector
- Richard G. VincentExecutive Officer
- Mark W. Surber, Ph.D.Executive Officer, Director
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Minimum investment
- $1
- First sale
- Oct 2011
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Robinhood5 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Avalyn Pharma Inc5 shared keywordsAvalyn Pharma is a clinical-stage biopharmaceutical company developing targeted inhaled therapies for patients with rare lung diseases, including pulmonary fibrosis and other interstitial lung diseases. Its lead inhaled therapies have advanced through global Phase 2 development for pulmonary fibrosis.
Seeking Alpha5 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Companies competing with Genoa Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Genoa Pharmaceuticals do?
- Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Its lead asset is inhaled pirfenidone (Aerodone), a nebulized reformulation designed to deliver effective lung levels while reducing the side effects of oral dosing.
- Who founded Genoa Pharmaceuticals?
- Genoa Pharmaceuticals was founded by Mark W. Surber, Ph.D. in 2011.
- Who are Genoa Pharmaceuticals's investors?
- Genoa Pharmaceuticals's investors include Norwest Venture Partners, RiverVest Venture Partners, Sofinnova Ventures.
- How much funding has Genoa Pharmaceuticals raised?
- Genoa Pharmaceuticals has disclosed $245.1M raised across 4 rounds.
- Where is Genoa Pharmaceuticals headquartered?
- Genoa Pharmaceuticals is headquartered in San Diego, US.